MIMEDX Comments on Recent Data Brief Published by Office of Inspector General
March 16, 2023 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., March 16, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today applauded the recent report...
MIMEDX Announces Fourth Quarter and Full Year 2022 Operating and Financial Results
February 28, 2023 16:01 ET
|
MiMedx Group, Inc
Reports Highest Quarterly Net Sales Since the Fourth Quarter of 2019 Quarterly Net Sales of $74.4 million Reflect Growth of 10% with Strong Contributions from Sales to the Surgical Market Initiated...
MIMEDX to Host Fourth Quarter and Full Year 2022 Operating and Financial Results Conference Call on February 28
February 15, 2023 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., Feb. 15, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it will report...
MIMEDX Appoints Joseph H. Capper as Chief Executive Officer and Director
January 30, 2023 08:00 ET
|
MiMedx Group, Inc
Highly experienced and accomplished three-time healthcare CEO with a proven track record of substantial value creation to lead MIMEDX MARIETTA, Ga., Jan. 30, 2023 (GLOBE NEWSWIRE) -- MiMedx Group,...
MIMEDX Confirms Fourth Quarter and Full Year 2022 Net Sales Expectations, Comments on Evolving Medicare Reimbursement Landscape and Provides Corporate Updates
January 09, 2023 08:02 ET
|
MiMedx Group, Inc
Fourth quarter and full year 2022 net sales expected in the ranges of $73 million to $76 million and $266 million to $269 million, respectively Provides commentary regarding the potential impact of...
MIMEDX Announces Commercial Launch of EPIFIX® in Japan with Exclusive Distribution Agreement with GUNZE MEDICAL LIMITED
January 04, 2023 16:01 ET
|
MiMedx Group, Inc
MIMEDX aligns with a leading distributor of wound care products in Japan to capitalize on first-mover advantage for EPIFIX MARIETTA, Ga. and OSAKA, Japan, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MiMedx...
MIMEDX Appoints Ricci S. Whitlow as Chief Operating Officer
January 03, 2023 08:00 ET
|
MiMedx Group, Inc
MIMEDX bolsters management team with 30+ year MedTech veteran with extensive operational leadership MARIETTA, Ga., Jan. 03, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or...
MIMEDX Announces Wound & Surgical Product Pipeline Expansion via In-Licensing and Distribution Agreement with Turn Therapeutics
December 08, 2022 08:00 ET
|
MiMedx Group, Inc
Agreement provides MIMEDX with exclusive rights to Turn’s PermaFusion® proprietary antimicrobial intellectual property (IP), accelerating the product development pipeline for wound and surgical...
MIMEDX to Present at Upcoming Investor Conferences
November 10, 2022 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., Nov. 10, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management...
MIMEDX Announces Third Quarter 2022 Operating and Financial Results
November 02, 2022 16:15 ET
|
MiMedx Group, Inc
Third Quarter Net Sales of $67.7 Million Reflect Growth of 7.3% Introducing Wound & Surgical and Regenerative Medicine Segment Reporting to Highlight Trends Within Each Business Unit Third...